223 related articles for article (PubMed ID: 28928856)
1. The Putative Role of
Semczuk A; Gogacz M; Semczuk-Sikora A; Jóźwik M; Rechberger T
J Cancer; 2017; 8(14):2684-2691. PubMed ID: 28928856
[TBL] [Abstract][Full Text] [Related]
2. Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase IIα) in borderline ovarian tumors: Correlation with clinicopathological features.
Ciepliński K; Jóźwik M; Semczuk-Sikora A; Gogacz M; Lewkowicz D; Ignatov A; Semczuk A
Histol Histopathol; 2018 Feb; 33(2):171-179. PubMed ID: 28493257
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
4. Second primary or recurrence? Comparative patterns of p53 and K-ras mutations suggest that serous borderline ovarian tumors and subsequent serous carcinomas are unrelated tumors.
Ortiz BH; Ailawadi M; Colitti C; Muto MG; Deavers M; Silva EG; Berkowitz RS; Mok SC; Gershenson DM
Cancer Res; 2001 Oct; 61(19):7264-7. PubMed ID: 11585764
[TBL] [Abstract][Full Text] [Related]
5. Survival of women with ovarian carcinomas and borderline tumors is not affected by estrogen and progesterone receptor status.
Sallum LF; Sarian LO; Lucci De Angelo Andrade L; Vassallo J; Soares FA; Pinto GA; Ferreira PA; Derchain S
J Gynecol Oncol; 2013 Apr; 24(2):167-76. PubMed ID: 23653835
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic analysis of low-stage sporadic ovarian carcinomas: a reappraisal.
Karamurzin Y; Leitao MM; Soslow RA
Am J Surg Pathol; 2013 Mar; 37(3):356-67. PubMed ID: 23282975
[TBL] [Abstract][Full Text] [Related]
7. Prognosis in patients with serous and mucinous stage I borderline ovarian tumors.
Song T; Lee YY; Choi CH; Kim TJ; Lee JW; Kim BG; Bae DS
Int J Gynecol Cancer; 2012 Jun; 22(5):770-7. PubMed ID: 22426410
[TBL] [Abstract][Full Text] [Related]
8. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors.
Giurgea LN; Ungureanu C; Mihailovici MS
Rom J Morphol Embryol; 2012; 53(4):967-73. PubMed ID: 23303020
[TBL] [Abstract][Full Text] [Related]
9. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical significance of vascular endothelial growth factor, cyclooxygenase-2, and Bcl-2 in borderline ovarian tumors.
Li M; Qi SY; Wang Y; Feng SX; Zhang BZ; Wang R
Arch Gynecol Obstet; 2005 Jun; 272(1):48-52. PubMed ID: 15682318
[TBL] [Abstract][Full Text] [Related]
11. MORPHOPHENOTYPIC CHARACTERISTICS OF OVARIAN SEROUS BORDERLINE TUMORS.
Munjishvili V; Barabadze E; Musashvili T; Gachechiladze M; Burkadze G
Georgian Med News; 2019 May; (290):20-25. PubMed ID: 31322508
[TBL] [Abstract][Full Text] [Related]
12. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors.
Lu KH; Bell DA; Welch WR; Berkowitz RS; Mok SC
Cancer Res; 1998 Jun; 58(11):2328-30. PubMed ID: 9622067
[TBL] [Abstract][Full Text] [Related]
13. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of microinvasion in borderline ovarian tumors and its impact on surgical management.
Ferrero A; Strada I; Di Marcoberardino B; Maccarini LR; Pozzati F; Rossi M; Biglia N; De Iaco P
Int J Gynecol Cancer; 2012 Sep; 22(7):1158-62. PubMed ID: 22801031
[TBL] [Abstract][Full Text] [Related]
15. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
16. P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
Gursan N; Sipal S; Calik M; Gundogdu C
Eurasian J Med; 2009 Apr; 41(1):10-4. PubMed ID: 25610057
[TBL] [Abstract][Full Text] [Related]
17. New sonographic marker of borderline ovarian tumor: microcystic pattern of papillae and solid components.
Timor-Tritsch IE; Foley CE; Brandon C; Yoon E; Ciaffarrano J; Monteagudo A; Mittal K; Boyd L
Ultrasound Obstet Gynecol; 2019 Sep; 54(3):395-402. PubMed ID: 30950132
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
19. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors.
Caduff RF; Svoboda-Newman SM; Ferguson AW; Johnston CM; Frank TS
Am J Surg Pathol; 1999 Mar; 23(3):323-8. PubMed ID: 10078924
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic extended usefulness of RMI: comparison of four risk of malignancy index in preoperative differentiation of borderline ovarian tumors and benign ovarian tumors.
Zhang S; Yu S; Hou W; Li X; Ning C; Wu Y; Zhang F; Jiao YF; Lee LTO; Sun L
J Ovarian Res; 2019 Sep; 12(1):87. PubMed ID: 31526390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]